OBJECTIVES: Using the type of meal and dosing conditions suggested by regulatory agencies as a basis, this review has two specific objectives: first, to summarize our understanding on the impact of food intake on luminal environment and drug product performance and second, to summarize the usefulness and limitations of available in vitro and in silico methodologies for the evaluation of drug product performance after food intake. KEY FINDINGS: Characterization of the luminal environment and studies evaluating product performance in the lumen, under conditions suggested by regulatory agencies for simulating the fed state, are limited. Various in vitro methodologies have been proposed for evaluating drug product performance in the fed state, but systematic validation is lacking. Physiologically based pharmacokinetic (PBPK) modelling approaches require the use of in vitro biorelevant data and, to date, have been used primarily for investigating the mechanisms via which an already observed food effect is mediated. SUMMARY: Better understanding of the impact of changes induced by the meal administration conditions suggested by regulatory agencies on the luminal fate of the drug product is needed. Relevant information will be useful for optimizing the in vitro test methods and increasing the usefulness of PBPK modelling methodologies.
OBJECTIVES: Using the type of meal and dosing conditions suggested by regulatory agencies as a basis, this review has two specific objectives: first, to summarize our understanding on the impact of food intake on luminal environment and drug product performance and second, to summarize the usefulness and limitations of available in vitro and in silico methodologies for the evaluation of drug product performance after food intake. KEY FINDINGS: Characterization of the luminal environment and studies evaluating product performance in the lumen, under conditions suggested by regulatory agencies for simulating the fed state, are limited. Various in vitro methodologies have been proposed for evaluating drug product performance in the fed state, but systematic validation is lacking. Physiologically based pharmacokinetic (PBPK) modelling approaches require the use of in vitro biorelevant data and, to date, have been used primarily for investigating the mechanisms via which an already observed food effect is mediated. SUMMARY: Better understanding of the impact of changes induced by the meal administration conditions suggested by regulatory agencies on the luminal fate of the drug product is needed. Relevant information will be useful for optimizing the in vitro test methods and increasing the usefulness of PBPK modelling methodologies.
Authors: Xavier J H Pepin; James E Huckle; Ravindra V Alluri; Sumit Basu; Stephanie Dodd; Neil Parrott; Arian Emami Riedmaier Journal: AAPS J Date: 2021-01-04 Impact factor: 4.009
Authors: Mark McAllister; Talia Flanagan; Susan Cole; Andreas Abend; Evangelos Kotzagiorgis; Jobst Limberg; Heather Mead; Victor Mangas-Sanjuan; Paul A Dickinson; Andrea Moir; Xavier Pepin; Diansong Zhou; Christophe Tistaert; Aristides Dokoumetzidis; Om Anand; Maxime Le Merdy; David B Turner; Brendan T Griffin; Adam Darwich; Jennifer Dressman; Claire Mackie Journal: Pharmaceutics Date: 2022-05-07 Impact factor: 6.525
Authors: Heino Stass; Ethel Feleder; Facundo Garcia-Bournissen; Johannes Nagelschmitz; Boris Weimann; Gustavo Yerino; Jaime Altcheh Journal: Clin Pharmacol Drug Dev Date: 2020-10-08